84064-16-4

Usage

Uses

Used in Pharmaceutical Applications:
N-trans-cinnamoyl-DL-alanine is used as a potential therapeutic agent for [application reason] due to its antioxidant, anti-inflammatory, and cytotoxic properties. It is being investigated for its potential use in the development of new drugs for various medical conditions.
Used in Antioxidant and Anti-inflammatory Applications:
N-trans-cinnamoyl-DL-alanine is used as an antioxidant and anti-inflammatory agent for [application reason], such as reducing oxidative stress and inflammation in the body.
Used in Cancer Research:
In the field of cancer research, N-trans-cinnamoyl-DL-alanine is used as a cytotoxic agent for [application reason], such as targeting and eliminating cancer cells in laboratory studies.
Used in the Development of New Drugs:
N-trans-cinnamoyl-DL-alanine is used as a key compound in the development of new drugs for [application reason], as its unique properties may contribute to the creation of novel therapeutic options for various medical conditions.
(Note: The "application reason" should be filled in with specific reasons based on the intended use of the compound, such as treating a particular disease, improving drug delivery, or enhancing the effectiveness of existing treatments.)

Upstream product

• 102-92-1 Cinnamoyl chloride 
• 302-72-7 rac-Ala-OH 

Relevant academic research and scientific papers

Anti-Helicobacter pylori activities of selected N-substituted cinnamamide derivatives evaluated on reference and clinical bacterial strains

In this study, thirty-five N-substituted derivatives of cinnamic acid amide (cinnamamide) were evaluated for anti-Helicobacter pylori activity using an agar disc-diffusion method. Qualitative screening was performed on a reference H. pylori strain (ATCC 43504), resulting in the identification of the three most active compounds, 8 (R,S-(2E)-3-(4-chlorophenyl)-N-(2-hydroxypropyl)prop-2-enamide, minimal inhibitory concentration, MIC = 7.5 μg/mL), 23 ((2E)-3-(4-chlorophenyl)-N-(2-hydroxycyclohexyl)prop-2-enamide, MIC = 10 μg/mL), and 28 ((2E)-3-(4-chlorophenyl)-N-(4-oxocyclohexyl)prop-2-enamide, MIC = 10 μg/mL). These compounds were further tested on twelve well-characterized clinical strains, yielding MIC values that ranged from 10 to 1000 μg/mL. Preliminary safety assessments of the compounds were made using the MTT viability test for cytotoxicity and Ames test for mutagenicity, which showed them to be generally safe, although compounds 8 and 28 showed mutagenic activity at some of the tested concentrations. The results of this study showed the anti-H. pylori potential of cinnamamide derivatives.